Modulation of immune mediated diseases of the eye;Pharmakologische modulation immunmediierter erkrankungen des auges

Klinische Monatsblatter fur Augenheilkunde

Volumn 214, Issue 3, 1999, Pages 160-170

  Pleyer, Uwe ^a   Liekfeld, Anja ^a   Baatz, Holger ^a   Hartmann, Christian ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Immunmodulation; Immunology; Inflammation; Keratoplasty; Uveitis

Indexed keywords

15 DEOXYSPERGUALIN; AZATHIOPRINE; BROMOCRIPTINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOMODULATING AGENT; LEFLUNOMIDE; METHOTREXATE; MONOCLONAL ANTIBODY; RAPAMYCIN; TACROLIMUS;

CONFERENCE PAPER; CORTICOSTEROID THERAPY; EYE DISEASE; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOPHARMACOLOGY; IMMUNOTHERAPY; IMMUNOTOXICITY;

EID: 0032960443     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1034769     Document Type: Conference Paper

References (106)

1. Althaus C, Dagres E, Reinhard T, Christians U, Sundmacher R. Ciclosporin-A and its metabolites in the anterior chamber after topical and systemic application as determined with high-performance liquid chromatography-electrospray mass spectrometry. Ger J Ophthalmol 1996; 5:189-194
2. Amemiya H, Dodi K, Otsuba O et al. Markedly enhanced therapeutic effect of desoxyspergualin on acute rejection when combined with methylprednisolone in kidney recipients. Transpl Proc 1991; 23:1087-1090
3. Atalla L, Linker-Israeli M, Steinman L, Rao NA. Inhibition of autoimmune uveitis by anti-CD4 antibody. Invest Ophthalmol Vis Sci 1990; 31:1264-1270
4. Bach JF, Fracchia GN, Chatenoud L. Safety and efficacy of therapeutic monoclonal antibodies in clinical trials. Immunol Today 1993; 14:421-425
5. Bartlett RR, Dimitrijevic M, Mattar T et al. Leflunomide (HWA486), a novel immuno-modulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection. Agents Actions 1991;32:10-21
6. Beato M. Gene regulation by steroid hormones. Cell 1989; 56:335-344
7. Beck RW, Cleary P, Tobe JD et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 1993; 329:1764-1769
8. Bell TAG, Easty DL, McCullagh KG. A placebo-controlled blind trial of cyclosporin-A in prevention of corneal graft reaction in rabbits. Br J Ophthalmol 1982; 66:303-308
9. Belin MW, Bouchard CS, Philips TM. Update on topical Cyclosporin A. Background, immunology and pharmacology. Cornea 1990; 9:184-195
10. BenEzra D, Pe'er J, Brodsky M, Cohen E. Cyclosporine eye drops for the treatment of severe vernal keratokonjunctivitis. Am J Ophthalmol 1986; 101:278-282
11. Binder AI, Graham EM, Sanders MD. Cyclosporin in the treatment of severe Behçet's uveitis. Br J Rheumatol 1987; 26:285-291
12. Bouroncle BA, Smith EJ, Cuppage FE. Treatment of Wegener's granulomatosis with Imuran. Am J Med 1967; 42:314-318
13. Borel JF. Pharmacology of cyclosporine (Sandimmune). Pharmacol. Rev. 1989; 41-53
14. Brown SI, Mondino BJ. Therapy of Mooren's ulcer. Am J Ophthalmol 1984; 98:1-6
15. Chan HS, Grogan TM, DeBoer G, Haddad G, Gallie BL, Ling V. Diagnosis and reversal of multidrug resistance in paediatric cancers. Eur J Cancer 1996; 32:1051-1061
16. Cobbold SP, Jayasuriya A, Nash A, Prospero TD, Waldmann H. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature 1984; 312:548-55
17. Coggins PR, Randin RG, Eisman SM. Clinical pharmacology and preliminary evaluation of cyclophosphamide. Cancer Chemother Rep 1959; 3:9-11
18. Corley CC, Lessner SE, Larsen WE. Azathioprine therapy of "autoimmune" diseases. Am J Med 1966; 41:404-412
19. Dumont FJ, Starvch MJ, Koprak SL, Melino MR, Segal NH. Distinct mechanisms of suppression of murine T cell acitivation by the related macrolides FK506 and rapamycin. J Immunol 1990; 144:251-256
20. Falk W, Ulrichs K, Müller-Ruchholtz W. 15-Deoxyspergualin blocks T lymphoycte proliferation. Transpl Proc 1987; 19:4239-4242
21. Fischer G, Witman-Liebold B, Lang K, Kiefhaber T, Schmid FY. Cyclophilin and peptidyl-propyl cis-trans isomerase are probably identical proteins. Nature 1989; 337:476
22. Foets B, Missotten L, Vanderveren P, Goossens W. Prolonged survival of allogeneic corneal grafts in rabbits treated with topically applied cyclosporin A: systemic absorption and local immunosuppressive effect. Br J Ophthalmol 1985; 69:600-603
23. Foster CS, Fortstot SL, Wilson LA. Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Effects of systemic immunosuppression. Ophthalmology 1984; 91:1253-1263
24. Foster CS. Cicatricial pemphigoid. Trans Am Ophthalmol Soc 1986; 84:527-663
25. Friedberg M, Pleyer U, Mondino BJ. Device Drug Delivery: Collagen Shields, Iontophoresis, Pumps. Ophthalmology 1991; 98:725-732
26. Gilman AG, Goodman LS, Rall TW, Murad F. The pharmaocological basis of therapeutics. New York: Macmillan Publishing company 1985; 1247-1253
27. Granelli-Piperno A. Lymphokine gene expression in vivo is inhibited by cyclosporin A. J Exp Med 1990; 171:533
28. Harrison RN, Lippman SS. How steroid hormones work. Hosp Prac 1989; 24:63-76
29. He YG, Ross J, Niederkorn JK. Promotion of murine orthotopic corneal allograft survival by systemic administration of anti-CD4 monoclonal antibody. Invest Ophthalmol Vis Sci 1991; 32:2723-2728
30. He YG, Mellon J, Apte R, Niederkorn JK. Effect of LFA-1 and ICAM-1 antibody treatment on murine cornea allograft survival. Invest Ophthalmol Vis Sci 1994; 35:3218-3225
31. Hedner LP, Bynke G. Endogenous iridocyclitis is relieved during treatment with bromocriptine. Am J Ophthalmol 1985; 100:618-619
32. Herbort CP, deSmet MD, Roberge FG, Nussenblatt RB, Lorberboum-Galski H, Pastan I. New immunosuppressive approach to corneal graft rejection: a clinical and immunological study in a rat pkp-model. Ocular Immunology Today. Elsevier Science Publisher 1990; p 415-419
33. Herzog C, Walker C, Pichler W. Monoclonal anti-CD4 in arthritis. Lancet 1987; 2:1461-1463
34. Hoang-Xuan T, Foster CS, Rice BA. Scleritis in relapsing polychondritis: response to therapy. Ophthalmology 1990; 97:892-898
35. Hoffmann F, Wiederholt M. Local treatment of necrotizing scleritis with cyclosporin A. Cornea 1985; 4:3-7
36. Hoffmann F, Kruse HA, Meinhold H, Bechrakis NE, Heimann H, Diamantstein T. Interleukin-2 receptor-targeted therapy by monoclonal antibodies in the rat corneal graft. Cornea 1994;13:440-446
37. Holz FG, Krastel H, Breitbart A, Schwarz-Eywill M, Pezzutto A, Völcker HE. Low-dose methotrexate treatment in noninfectious uveitis resistant to corticosteroids. German J Ophthalmol 1992; 1:142-144
38. Hill JC. The use of cyclosporine in high-risk keratoplasty. Am J Ophthalmol 1989; 107:506-510
39. Imperia PS, Lazarus HM, Lass JH. Ocular complications of systemic cancer chemotherapy. Surv Ophthalmol 1990; 34:209-231
40. Ippoliti G, Fronterrè A. Usefulness of CD3 or CD6 anti-T monoclonal antibodies in the treatment of acute corneal graft rejection. Transplant Proc 1989; 21:3133-3134
41. Isaak BL, Liesegang TJ, Michel CJ. Ocular and systemic findings in relapsing polychondritis. Ophthalmology 1986; 93:681-689
42. Ishioka M, Ohno S, Nakamura S et al. FK506 treatment of noninfectious uveitis. Am J Ophthalmol 1994; 118:723-729
43. Kahan BD, Chang JY, Seghal SN. Preclinical evaluation of a new potent immunosupressive agent, rapamycin. Transplantation 1991; 185-191
44. Kana JS, Hoffmann F, Buchen R. Rabbit corneal allograft survival following topical administration of cyclosporin A. Invest Ophthalmol Vis Sci 1982; 22:686-690
45. Kaufman HE. Practical considerations in the selection of anti-inflammatory agents. Trans Am Acad Ophthalmol Otolaryngol 1975; 79:89-95
46. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495-497
47. Larson DF. Mechanism of action: antagonism of the prolactin receptor. Prog Allergy 1986; 38:222-238
48. Lazar M, Weiner MJ, Leopold IH. Treatment of uveitis with methotrexate. Am J Ophthalmol 1969; 7:383-387
49. Leibowitz HM, Kupferman A. Kinetics of topically administered prednisolone acetate. Arch Ophthal 1976; 94:1387-1389
50. McChesney L, Xiao F, Sankary H, et al. Evaluation of leflunomide in the canine renal transplantation model. American Society of Transplantation Surgeons 1993; B-3:73 (Abstr.)
51. Martenet AC. Resultats de l'immunodepression par cytostatiques en ophthalmologie. Ophthalmologica 1976; 172:106-115
52. Milani J, Pleyer U, Dukes A, Chou HJ, Lutz S, Rückert D, Schmidt KH, Mondino BJ. Prolongation of corneal allograft survival with liposome-encapsulated cyclosporine in the rat eye. Ophthalmology 1993; 100:890-896
53. Milani JK, Verbukh I, Pleyer U, Sumner H, Adamu SA, Halabi HJ, Chou HJ, Lee DA, Mondino BJ. Collagen shields impregnated with gentamycin-dexamethasone combination as a potential drug delivery device. Am J Ophthalmol 1993; 116:622-627
54. Miller K, Huber C, Niederwieser D, Göttinger W. Succsessful engraftment of high-risk corneal allografts with short-term immunosuppression with cyclosporine. Transplantation 1988; 45:651-653
55. Mondino BJ, Brown SI. Immunosuppressive therapy in ocular cicatricial pemphigoid. Am J Ophthalmol 1983; 96:453-459
56. Nadler SG, Tepper MA, Schacter B, Mazzucco CE. Interaction of the immunosuppressant deoxyspergualin with a member of the Hsp 70 family of heat shock proteins. Science 1992; 258:484-486
57. Nagy E, Berczi I, Wren GE, et al. Immunomodulation by bromocriptine. Immunopharmacology 1983; 6:231-243
58. Nakata S, Ito T, Furuzana M, Nakano S. Immunosuppressive mechanisms of 15-desoxyspergualin on heterotopic heart transplantation in rats. Trans Proc 1991; 23:864-865
59. Nierenberg DW. Methotrexate therapy for psoriasis. JAMA 1988; 260:3303
60. Nishi M, Herbort CP, Matsubara M, Morishita Y, Nishimura M, Nieda M, Mori S, Mochizuki M. Effects of the immunosuppressant FK506 on a penetrating keratoplasty rejection model in the rat. Invest Ophthalmol Vis Sci 1993; 34:2477-2486
61. Nussenblatt RB, Palestine AG, Chan CC. Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol 1983; 96:275-282
62. Nussenblatt RB, Palestine AG. Cyclosporine: Immunology, pharmacology and therapeutic uses. Surv Ophthalmol 1986; 31:159-169
63. Holland EJ, Olsen TW, Sterrer J, Ketchum JM, Mindrup EA, Gruber SA. Suppression of graft rejection using 15-deoxyspergualin in the allogeneic penetrating keratoplasty model. Cornea 1994; 13:28-32
64. Olsen TW, Benegas NM, Joplin AC, Evangelista T, Mindrup EA, Holland EJ. Rapamycin inhibits corneal allograft rejection and neovascularization. Arch Ophthalmol 1994; 112:1471-1475
65. Palestine AG, Muellenberg-Coulombre CG, Kim MK et al. Bromocriptine and low dose cyclosporine in the treatment of experimental autoimmune uveitis in rats. J Clin Invest 1987; 79:1078-1081
66. Pavan-Langston D, Dunkel EC. Handbook of ocular drug therapy and ocular side effects of systemic drugs. Boston/Toronto/London: Little, Brown and Company 1991
67. Pleyer U, Weidle EG, Thiel HJ. The use of cyclosporine in high-risk keratoplasty. Am J Ophthalmol 1989; 108:467-468
68. Pleyer U, Gupta D, Weidle EG, Lisch W, Zierhut M. Thiel HJ. Elevated prolactin levels in human aqueous humor of patients with anterior uveitis. Graefe Arch Ophthalmol 1991; 229:447-451
69. Pleyer U, Rückert D, Bachmann W, Schmidt KH, Thiel HJ. Intraokulare Verfügbarkeit liposomenverkapselter monoklonaler Antikörper im Kaninchenmodell. Ergebnisse einer Pilotstudie. Fortschr Ophthalmol 1991; 88:870-874
70. 69a Pleyer U, Steuhl KP, Weidle EG, Lisch W, Thiel H-J. Corneal graft rejection: Incidence, manifestation, and interaction of clinical subtypes. Transplant Proc 1992; 24:2034-2037, 1992
71. Pleyer U, Lutz S, Jusko WJ, Nguyen K, Narawane M, Rückert D, Mondino BJ, Lee VHL. Ocular absorption of topically applied FK506 from liposomal and oil formulations in the rabbit eye. Invest Ophthalmol Vis Sci 1993; 34:2737-2742
72. Pleyer U, Raphael B, Kosmidis P, Ryffel B, Thiel HJ. Verteilung von Cyclophilin in okulären Geweben. Ophthalmologe 1993; S90:118
73. Pleyer U, Zierhut M, Thiel HJ. Antibodies as preventive/therapeutic agents in corneal graft rejection. In: Zierhut M, Pleyer U, Thiel HJ (Eds) Immunology of corneal transplantation. Buren: Aeolus Press 1994; pp 263-275
74. Pleyer U, Elkins B, Rückert D, Lutz S, Grammer J, Chou J, Schmidt KH, Mondino BJ. Ocular absorption of cyclosporine A from liposomes incorporated into collagen shields. Curr Eye Res 1994; 13:177-181
75. Pleyer U, Milani JK, Dukes A, Chou J, Mondino BJ. Effect of liposome encapsulated anti-CD4 monoclonal antibodies on orthotopic corneal allografts in a rat model. Invest Ophthalmol Vis Sci 1995; 35:52-61
76. Ramadan AM, Nussenblatt RB, de Smet MD. Long-term follow-up of Patients with chronic Uveitis affecting the posterior pole treated with Combination Cyclosporine and Ketoconazole. Ophthalmology 1997; 104:706-711
77. Reinhard T, Sundmacher R. Lokale Ciclosporin A Therpie bei Keratitis superficialis punctata Thygeson - eine Pilotstudie. Klin Monatsbl Augenheilkd 1996; 209:224-227
78. Reinhard T, Sundmacher R. Lokale Ciclosporin A Therapie bei Nummuli nach Keratoconjunctivitis epidemica - Fallbericht. Klin Monatsbl Augenheilkd 1997; 210:165-168
79. Roberge FG, Lorberboum-Galski H, Le Hoang P. de Smet MD, Chan CC, Fitzgerald D, Pastan I. Selective immunosuppression of activated T cells with the chimeric toxin IL-PE40. J Immunol 1989; 143:3498-3501
80. Roberge FG, Xu D, Chan C-C, de Smet MD, Nussenblatt RB, Chen H. Treatment of autoimmune uveoretinitis in the rat with rapamycin, an inhibitor of lymphocyte growth factor signal transduction. Curr Eye Res 1993; 12:197-203
81. Rückert D, Pleyer U, Kasten B, Schem C, Lutz S, Schmidt KH, Thiel HJ. Ocular availability of liposome-encapsulated anti-CD3 monoclonal antibodies (OKT3). In: Pleyer U., Schmidt K.H., Thiel H.J. (eds.) Liposomes in Ophthalmology and Dermatology. Stuttgart: Thieme/Hippokrates 1993; pp 71-77
82. Seale JP, Compton MR. Side effects of corticosteroid agents. Med J Aust 1986; 144:139-142
83. Sehgal SR, Baker H, Vezina C. Rapamycin (AY-22, 989), a new antifugal antibiotic. II. Fermentation, isolation and characterization. J Antibiot 1975; 28:727-732
84. Shapiro R, Fung JJ, Jain A, Parks P, Todo S, Starzl TE. The side effects of FK506 in humans. Transplant Proc 1990; 22:41-43
85. Shupack JL, Webster GF. Pancytopenia following low-dose oral methotrexate therapy for psoriasis. JAMA 1988; 259:3594-3596
86. Sigal NH, Dumont FJ. Cyclosporin A, FK506 and rapamycin: pharmacologic probes of lymphocyte signal transduction. Ann Rev Immunol 1992; 10:519-560
87. Stammen J, Althaus C, Sundmacher R. Ulkus Mooren. Vier schwere beidseitige Verläufe unter systemischer Ciclosporin-A-Therapie. Klin Monatsbl Augenheilkd 1997; 211:306-311
88. Stover C, Otto E, Beyer J, Kahaly G. Die endokrine Orbitopathie. Aktuelle Aspekte zur Pathogenese und konservativen Therapie. Aktuelle Augenheilk 1993; 18:136-144
89. Sundmacher R, Reinhard T, Heering P. Six years experience with systemic Cyclosporin A prophylaxis in high risk perforating keratoplasty patients. Ger J Ophthalmol 1992; 1:432-436
90. Takahashi N, Hayano T, Suzuki M. Peptidyl-propyl cis-trans isomerase is the cyclosporin A-binding protein cyclophilin. Nature 1989; 337:473
91. Takeuchi T. A new antitumor antibiotic, spergualin: isolation and antitumor activity. J Antibiotics 1981; 34:1619-1623
92. Thiel HJ, Schmidt KH, Pleyer U. Lokaltherapie mit Liposomen. Dt Ärztebl 1993; 90:359-361
93. Thoenes GH, Sitter T, Langer KH, Bartlett RR, Schleyerbach R. Leflunomide (HWA 486) inhibits experimental autoimmune tubulointerstitial nephritis in rats. Int J Immunopharmacol 1989; 11:921-929
94. Thompson P, Xu D, Chen H, Brunette I. Effect of rapamycin and cyclosporin on corneal rejection in the rat penetrating keratoplasty model. Invest Ophthalmol Vis Sci 1993; 34:1101
95. Thurau SR, Wildner G, Reiter Chr, Riethmüller G, Lund OE. Treatment of endogenous uveitis with anti-CD4 monoclonal antibody: first report. Ger J Ophthalmol 1994; 3:409-413
96. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22, 989), a new antifungal antibiotic. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot 1975; 28:721-726
97. Waldmann H. Manipulation of T-cell responses with monoclonal antibodies. Annu Rev Immunol 1989; 7:407-444
98. Wakefield D, McCluskey P, Penny R. Intravenous pulse methylprednisolone therapy in severe inflammatory eye disease. Arch Ophthalmol 1986; 104:847-851
99. Walker KB, Potter JM, House AK. Interleukin 2 synthesis in the presence of steroids. A model of steroid resistance. Clin Exp Immunol 1987; 68:162-167
100. Watson PG. The nature and the treatment of scleral inflammation. Trans Ophthalmol Soc UK 1982; 102:257-281
101. Werkheiser W. The biochemical, cellular, and pharmacologic action and effects of folic acid antagonists. Cancer Res 1963; 23:1277-1285
102. Whitcup SM, Salvo EC, Nussenblatt RB. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behçet's disease. Am J Ophthalmol 1994; 118:39-45
103. Whitcup SM, DeBarge LR, Caspi RR, Harning R, Nussenblatt RB, Chan CC. Monoclonal antibodies against ICAM-1 and LFA-1 inhibits experimental autoimmune uveitis. Clin Immunol Immunopathol 1993; 67:143-150
104. Wiebking J, Mehlfeld T. Topical treatment of corneal ulcers and scleromalacias with cyclosporin A. Fortschr Ophthalmol 1986; 83:345-347
105. Wong VG. Methotrexate treatment of uveal disease. Am J Med Sci 1966; 251:239-241
106. Zierhut M, Thiel HJ, Weidle EG, Waetjen R, Pleyer U. The treatment of severe corneal ulcers with cyclosporin A eye drops. Graefe's Arch klin exp Ophthalmol 1989; 227:30-35